Guardant Health, Inc. (GH) stock
GHNasdaqServices-Medical LaboratoriesFiscal year ends December 31
$143.28−0.75 (-0.52%)
Close on Nov 17, 2026Market cap $19.23BP/E –Yield –
Guardant Health revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Guardant Health's revenue for the twelve months ending Jun 30, 2026 was $1.18B, up 42.7% year over year. For fiscal 2025 it was $982.02M, up 32.9% from the year before. The highest annual figure on record is $982.02M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $982.02M | +32.9% |
| FY2024 | Dec 31, 2024 | $739.02M | +31.0% |
| FY2023 | Dec 31, 2023 | $563.95M | +25.5% |
| FY2022 | Dec 31, 2022 | $449.54M | +20.3% |
| FY2021 | Dec 31, 2021 | $373.65M | +30.3% |
| FY2020 | Dec 31, 2020 | $286.73M | +33.8% |
| FY2019 | Dec 31, 2019 | $214.38M | +136.5% |
| FY2018 | Dec 31, 2018 | $90.64M | +81.9% |
| FY2017 | Dec 31, 2017 | $49.84M | +97.4% |
| FY2016 | Dec 31, 2016 | $25.25M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $334.98M | +44.3% |
| Q1 FY2026 | Mar 31, 2026 | $301.67M | +48.3% |
| Q4 FY2025 | Dec 31, 2025 | $281.27M | +39.4% |
| Q3 FY2025 | Sep 30, 2025 | $265.20M | +38.5% |
| Q2 FY2025 | Jun 30, 2025 | $232.09M | +30.9% |
| Q1 FY2025 | Mar 31, 2025 | $203.47M | +20.8% |
| Q4 FY2024 | Dec 31, 2024 | $201.81M | +30.2% |
| Q3 FY2024 | Sep 30, 2024 | $191.48M | +33.9% |
| Q2 FY2024 | Jun 30, 2024 | $177.24M | +29.2% |
| Q1 FY2024 | Mar 31, 2024 | $168.49M | +30.9% |
| Q4 FY2023 | Dec 31, 2023 | $155.05M | +22.2% |
| Q3 FY2023 | Sep 30, 2023 | $143.03M | +21.8% |
| Q2 FY2023 | Jun 30, 2023 | $137.15M | +25.7% |
| Q1 FY2023 | Mar 31, 2023 | $128.71M | +33.9% |
| Q4 FY2022 | Dec 31, 2022 | $126.89M | +17.4% |
| Q3 FY2022 | Sep 30, 2022 | $117.40M | +23.9% |
| Q2 FY2022 | Jun 30, 2022 | $109.14M | +18.5% |
| Q1 FY2022 | Mar 31, 2022 | $96.10M | +22.2% |
| Q4 FY2021 | Dec 31, 2021 | $108.11M | +38.0% |
| Q3 FY2021 | Sep 30, 2021 | $94.78M | +27.1% |
| Q2 FY2021 | Jun 30, 2021 | $92.10M | +38.8% |
| Q1 FY2021 | Mar 31, 2021 | $78.67M | +16.5% |
| Q4 FY2020 | Dec 31, 2020 | $78.32M | +24.5% |
| Q3 FY2020 | Sep 30, 2020 | $74.57M | +22.5% |
| Q2 FY2020 | Jun 30, 2020 | $66.34M | +22.9% |
| Q1 FY2020 | Mar 31, 2020 | $67.51M | +84.2% |
| Q4 FY2019 | Dec 31, 2019 | $62.90M | +91.3% |
| Q3 FY2019 | Sep 30, 2019 | $60.85M | +180.5% |
| Q2 FY2019 | Jun 30, 2019 | $53.98M | +178.5% |
| Q1 FY2019 | Mar 31, 2019 | $36.66M | +119.6% |
| Q4 FY2018 | Dec 31, 2018 | $32.87M | +64.3% |
| Q3 FY2018 | Sep 30, 2018 | $21.69M | +94.9% |
| Q2 FY2018 | Jun 30, 2018 | $19.38M | – |
| Q1 FY2018 | Mar 31, 2018 | $16.69M | – |
| Q4 FY2017 | Dec 31, 2017 | $20.00M | – |
| Q3 FY2017 | Sep 30, 2017 | $11.13M | – |
See a number that looks wrong?